Trials / Completed
CompletedNCT01837251
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 682 (actual)
- Sponsor
- AGO Research GmbH · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | |
| DRUG | PLD | |
| BIOLOGICAL | Bevacizumab |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
- First posted
- 2013-04-23
- Last updated
- 2021-07-13
Locations
193 sites across 6 countries: Australia, Austria, Belgium, France, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT01837251. Inclusion in this directory is not an endorsement.